What is the approximate price of Sorafenib/Nexavar in 2025?

Sorafenib/Nexavar (Sorafenib) is a small molecule multi-target tyrosine kinase inhibitor that is widely used in the treatment of advanced liver cancer, renal cell carcinoma, thyroid cancer and other solid tumors. By inhibiting the Raf kinase pathway and angiogenic factor receptors (such as VEGFR and PDGFR), it inhibits tumor cell proliferation and blocks the blood supply of tumors, thereby achieving the purpose of delaying disease progression. Especially in the field of advanced liver cancer, sorafenib is the first targeted drug approved for treatment. It is considered a landmark breakthrough in the treatment of liver cancer and brings new hope to advanced patients who previously lacked effective drugs.

Sorafenib is currently widely available in mainland China and has been included in the national medical insurance directory, greatly reducing the financial burden on patients. Taking the common domestic original research version "Nexavar" as an example, the specification is 0.2g*60 tablets, and the price per box is about 6,000 yuan. After being included in medical insurance, the actual payment amount of patients has dropped significantly, greatly improving accessibility. In addition, for patients with limited financial conditions or not covered by medical insurance, some overseas generic versions such as the Indian version of sorafenib are also attracting attention. The price of these generic drugs is usually between 500 and 1,000 yuan, and they are basically the same as the original drugs in terms of ingredients and mechanism of action. In particular, Indian generic drugs are more common in overseas shopping channels because of their affordable prices. However, patients need to pay attention to the formality of the source of the drug and the legality of the import.

From a clinical perspective, liver function, blood pressure, skin toxicity and other indicators need to be closely monitored during sorafenib treatment in order to adjust the dose or intervene in side effects in a timely manner. Although its treatment goal is to delay disease progression and improve survival time, because some patients may be intolerant to the drug or have poor efficacy, other new-generation targeted drugs such as donafenib or immune combination therapy may be needed in the future.

Reference materials:https://www.nexavar.com/